Scientific Names: 4-[(E)-2-(3,5-Dimethoxyphenyl)ethen-1-yl]phenol
Pterostilbene (PTS), a dimethylated derivative of resveratrol, is a natural compound primarily found in blueberries, almonds, grape leaves and vines, and Pterocarpus marsupium heartwood. It serves as a defensive phytoalexin in plants and is known for its enhanced bioavailability and potential health benefits compared to resveratrol. This increased effectiveness is attributed to the presence of two methoxy groups in PTS, which facilitate better oral absorption and stability. PTS has been studied for its therapeutic potential in various diseases, including diabetes, cancer, cardiovascular diseases, neurodegenerative disorders, and aging. It exhibits antioxidant and anti-inflammatory properties, influencing pathogenic pathways in these conditions. Despite its promising pharmacodynamic features, including better intestinal absorption and hepatic stability than resveratrol, there are concerns about its long-term cardiovascular risks due to its potential effects on cholesterol levels.
Most of the research on PTS is preclinical, with limited human trials. Studies have shown that it can influence cholesterol levels, potentially raising LDL ("bad cholesterol") and lowering HDL ("good cholesterol"). In terms of safety, it has been deemed safe for human consumption at dosages up to 250 mg per day, though comprehensive studies on its metabolic effects are lacking. As a result, while PTS is a promising compound due to its superior bioavailability and potential health benefits, further research and human clinical trials are needed to fully understand its therapeutic potential and safety profile.